|  |
| --- |
| **Subtype-specific alterations in the serological autoantibody profile of open-angle glaucoma patients** |
| Vanessa M. Beutgen, Norbert Pfeiffer, Franz H. Grus |

Supplementary Data

**S2 Supplementary file 2:** Post hoc test of significant ANOVA results. HSD test for unequal N was applied. Tables show respective P values.

**Table S2 - 1** ANOVA post hoc test for MCM7. HSD for unequal N.

|  |  |
| --- | --- |
| Group | Unequal N HSD; Variable: **MCM7** Marked (\*) differences are significant at p < .05000 |
|

|  |
| --- |
| {1}M=6.9070 |

 |

|  |
| --- |
| {2}M=7.1808 |

 |

|  |
| --- |
| {3}M=7.0444 |

 |

|  |
| --- |
| {4}M=7.4336 |

 |
|

|  |
| --- |
| NTG {1} |

 |  | 0,544786 | 0,909707 | 0,051964 |
|

|  |
| --- |
| CTRL {2} |

 | 0,544786 |  | 0,855649 | 0,461392 |
|

|  |
| --- |
| PEXG {3} |

 | 0,909707 | 0,855649 |  | 0,110207 |
|

|  |
| --- |
| POAG {4} |

 | 0,051964 | 0,461392 | 0,110207 |  |

**Table S2 - 2** ANOVA post hoc test for HTRA2. HSD for unequal N.

|  |  |
| --- | --- |
| Group | Unequal N HSD; Variable: **HTRA2** Marked (\*) differences are significant at p < .05000 |
|

|  |
| --- |
| {1}M=9.7078 |

 |

|  |
| --- |
| {2}M=10.070 |

 |

|  |
| --- |
| {3}M=9.5585 |

 |

|  |
| --- |
| {4}M=9.8786 |

 |
|

|  |
| --- |
| NTG {1} |

 |  | 0,333242 | 0,899597 | 0,857645 |
|

|  |
| --- |
| CTRL {2} |

 | 0,333242 |  | \* 0,021893 | 0,714546 |
|

|  |
| --- |
| PEXG {3} |

 | 0,899597 | \* 0,021893 |  | 0,287313 |
|

|  |
| --- |
| POAG {4} |

 | 0,857645 | 0,714546 | 0,287313 |  |

**Table S2 - 3** ANOVA post hoc test for HSP27. HSD for unequal N.

|  |  |
| --- | --- |
| Group | Unequal N HSD; Variable: **HSP27** Marked (\*) differences are significant at p < .05000 |
|

|  |
| --- |
| {1}M=12.015 |

 |

|  |
| --- |
| {2}M=11.856 |

 |

|  |
| --- |
| {3}M=12.369 |

 |

|  |
| --- |
| {4}M=11.870 |

 |
|

|  |
| --- |
| NTG {1} |

 |  | 0,873940 | 0,326848 | 0,899867 |
|

|  |
| --- |
| CTRL {2} |

 | 0,873940 |  | \* 0,016657 | 0,999844 |
|

|  |
| --- |
| PEXG {3} |

 | 0,326848 | \* 0,016657 |  | \* 0,023132 |
|

|  |
| --- |
| POAG {4} |

 | 0,899867 | 0,999844 | \* 0,023132 |  |

**Table S2 - 4** ANOVA post hoc test for CRYGS. HSD for unequal N.

|  |  |
| --- | --- |
| Group | Unequal N HSD; Variable: **CRYGS** Marked (\*) differences are significant at p < .05000 |
|

|  |
| --- |
| {1}M=13.745 |

 |

|  |
| --- |
| {2}M=13.558 |

 |

|  |
| --- |
| {3}M=14.192 |

 |

|  |
| --- |
| {4}M=13.560 |

 |
|

|  |
| --- |
| NTG {1} |

 |  | 0,789047 | 0,117142 | 0,794590 |
|

|  |
| --- |
| CTRL {2} |

 | 0,789047 |  | \* 0,000860 | 0,999999 |
|

|  |
| --- |
| PEXG {3} |

 | 0,117142 | \* 0,000860 |  | \* 0,001061 |
|

|  |
| --- |
| POAG {4} |

 | 0,794590 | 0,999999 | \* 0,001061 |  |

**Table S2 - 5** ANOVA post hoc test for CLTA/B/C. HSD for unequal N.

|  |  |
| --- | --- |
| Group | Unequal N HSD; Variable: **CLTA/B/C** Marked (\*) differences are significant at p < .05000 |
|

|  |
| --- |
| {1}M=11.166 |

 |

|  |
| --- |
| {2}M=10.891 |

 |

|  |
| --- |
| {3}M=8.6098 |

 |

|  |
| --- |
| {4}M=11.235 |

 |
|

|  |
| --- |
| NTG {1} |

 |  | 0,933870 | \* 0,000008 | 0,998844 |
|

|  |
| --- |
| CTRL {2} |

 | 0,933870 |  | \* 0,000008 | 0,813021 |
|

|  |
| --- |
| PEXG {3} |

 | \* 0,000008 | \* 0,000008 |  | \* 0,000008 |
|

|  |
| --- |
| POAG {4} |

 | 0,998844 | 0,813021 | \* 0,000008 |  |



**Figure S2 - 1** Box plot of HTRA2 autoantibody levels in CTRL, NTG, PEXG & POAG.



**Figure S2 - 2** Box plot of HSP27 autoantibody levels in CTRL, NTG, PEXG & POAG.



**Figure S2 - 3** Box plot of CRYGS autoantibody levels in CTRL, NTG, PEXG & POAG.